FindTrial
Sign In

Safety and efficacy of selective COX-2 inhibitor in compensated cirrhosis

Safety and efficacy of selective COX-2 inhibitor in compensated cirrhosis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200061116
Enrollment
Unknown
Registered
2022-06-15
Start date
2022-06-01
Completion date
Unknown
Last updated
2023-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver cirrhosis

Interventions

Control group:non-iCOX-2
COX-2 inhibitor group:iCOX-2

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Above the age of 18; 2. Diagnosed with liver cirrhosis through imaging or liver histopathologic examinations; 3. Willing to participate in the study and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Pregnant or breast-feeding women; 2. History of any decompensation events: esophagogastric variceal bleeding, hepatic encephalopathy, or ascites; 3. Child-Pugh score = 10; 4. Allergic to non-steroidal anti-inflammatory drugs (NSAIDs) or sulfonamides; 5. History of long-term intake of NSAIDs. 6. Other contradictions of COX-2 inhibitors, such as active peptic ulceration or gastrointestinal bleeding, severe heart failure, or history of coronary artery bypass.

Design outcomes

Primary

MeasureTime frame
Liver histology;HVPG;Liver-related clinical events;—

Secondary

MeasureTime frame
Liver biochemistry and liver function score;Serum markers of fibrosis;Liver stiffness by US;—

Countries

China

Contacts

Public ContactJinhang Gao

West China Hospital, Sichuan University

gao.jinhang@scu.edu.cn+86 19983187980

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026